December 10, 2024 — A pitched battle is underway. The fight is for equitable access to obesity medicines that can be life-changing for people living with obesity. Right now, we have a bit of a stalemate and money is the sticking point. So when Andrew Ross Sorkin put the question of greed, economics, and health to the CEO of […]
February 18, 2024 — Who knew that financial toxicity was a thing? Perhaps like us, you have merely thought of it as the financial burden of healthcare – without assigning it the status of a medical complication that dysfunctional healthcare causes. But recent publications are making it ever more clear that people living with chronic diseases are having to […]
July 28, 2023 — Obesity care is in an awkward phase. Science has advanced to provide a better understanding of this complex disease and better tools to treat it. But health systems and public understanding can’t keep up. As a result, very effective new obesity medicines exist behind walls that keep most people from receiving their benefits. For now, […]
May 8, 2023 — Semaglutide for the treatment of obesity continues to be in short supply. Late last week, Novo Nordisk announced that, because the company is still having difficulty keeping up with demand, they would limit production of the lower doses used to start patients on Wegovy. Thus, compounding pharmacies are selling cheap copies of semaglutide injection and […]
July 8, 2021 — This is seriously messed up. Let’s consider the case of two innovative new drugs and how health insurance will cover them. Each of them treats a chronic disease that can devastate a person’s health and quality of life. But these are different diseases and very different drugs. One offers a breakthrough in effectiveness. In fact, […]
